PATENT CLAIM ANALYSIS

Application Number: 16108121
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-02
Patent Classification: ["514", "419000"]

Abstract:
Pharmaceutical compositions of selective EP2 antagonists exemplified by small molecules TG4-155 and TG6-10-1 effective for treating gliomas, and methods for administering the pharmaceutical compositions to treat subjects suffering from disorders characterized by gliomagenesis.

Claim (Index 10):
The method according to  claim 9 , wherein the downstream PE2 signaling comprises PGE2-mediated cAMP signaling.

Metadata:
- Claim Count in Document: 29.0
- Percentile: 96.0
- Lexical Diversity: 1.12903
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15365850', '14852378', '14126689', '15533842', '13514884']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7286188705174433
- 35 USC 102 Novelty (BERT): 0.5232348525445791
- Combined Prediction Score: 0.708080468720157
- Mean Citation Score: 198.459238
- Max Citation Score: 201.17175
- Similarity Product: 94.03251712294669

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test